In a major step forward for global healthcare, Uganda’s Dei BioPharma has secured two U.S. patents for breakthrough therapies aimed at making cancer and immune treatments more affordable and accessible. The Kampala-based biotech firm, founded by Ugandan scientist Dr. Matthias Magoola, received confirmation from the United States Patent and Trademark Office (USPTO) on July 21, 2025.
The first innovation is a universal messenger RNA (mRNA) cancer vaccine that targets “cold” tumors—those that typically evade detection by the immune system—and turns them “hot,” or responsive to immune attack. Unlike traditional cancer vaccines that are customized for each patient, this vaccine uses generic antigens delivered via lipid nanoparticles to activate the body’s immune system broadly.
Preclinical trials have shown promising results, including complete tumor shrinkage and up to 90% protection against recurrence. The vaccine also works well with other treatments like anti-PD-1 therapies and is designed to help the immune system recognize a wide range of tumor markers.
This technology has positioned Dei BioPharma as a leader in cancer immunotherapy, showing that advanced solutions can come from Africa and compete on a global stage.
The second patented platform is a next-generation single-chain variable fragment (scFv) biologic that targets IL-23p19, a key cytokine involved in immune diseases. Existing treatments like Skyrizi® and Tremfya® use full-sized antibodies and come at a high cost. Dei BioPharma’s version is compact, affordable, and fused with proteins like albumin or transferrin to extend its effect in the body.
This biologic can be delivered in multiple ways—including nasal sprays, inhalers, creams, or patches—making it suitable for a variety of healthcare settings, including remote clinics. Its production in microbial systems cuts costs by up to 80%, while its small size improves how well it can enter tissues.
“These patents are not just scientific achievements—they are moral declarations,” said Dr. Magoola. “We’re proving that life-saving medicine doesn't have to be a luxury for the wealthy.”
Dr. Magoola, recently honored with Uganda’s “Faces of Science” award, said his goal is to ensure these therapies reach everyone, from top hospitals in wealthy nations to underserved areas in Africa and beyond.
Health
First U.S. Human Case of Travel-Linked Screwworm Confirmed by HHS
The U.S. has confirmed its first human case of New World Screwworm infestation linked to international travel, health officials announced.
Africa CDC Reports Drop in Mpox Cases, Warns of New Outbreaks
The Africa Centres for Disease Control and Prevention (Africa CDC) has reported a major 58 per cent drop in mpox cases across the continent between epidemiological week 19 and week 30 of 2025.
CS Duale Suspends 40 Hospitals Over SHA Insurance Fraud
Defence Cabinet Secretary Aden Duale has suspended 40 hospitals and 12 health officials over allegations of defrauding the Social Health Authority (SHA) system.
RFK Jr. Cancels $500M in mRNA Vaccine Projects Over Safety Concerns
The U.S. government is canceling $500 million worth of vaccine development projects that use mRNA technology, Health and Human Services (HHS) Secretary Robert F.
Nigerian Nurses Suspend Strike After Talks With Government
The nationwide warning strike by Nigerian nurses and midwives has been suspended following a closed-door meeting with government officials.
Mpox Outbreak: 314 Cases and 5 Deaths Reported in 22 Counties
The Ministry of Health has confirmed 314 Mpox cases and five related deaths across 22 counties in Kenya so far.
WHO Labels Hepatitis D a Cancer Risk, Urges Global Action
The World Health Organization (WHO) has classified Hepatitis D as a cancer-causing virus, warning that it significantly increases the risk of liver cancer in people already infected with Hepatitis B.